Citigroup Expects Acorda Therapeutics To Be Profitable

Acorda Therapeutics, Inc.

reported a solid Q3 driven by strong sales and tight exp Controls, Citigroup reports. From now on, the company said that Acorda will be profitable but demand for Ampyra will slow down after the initial pent-up demand is exhausted. “We still think this is a growth franchise but are trimming our ests in the out years,” Citigroup writes. “As docs are cooling a bit and reimbursement landscape is tough, sales growth will moderate. Our new TP is $29, assuming Acorda remains independent.” Acorda Therapeutics currently trades at $25.05.